148
Views
0
CrossRef citations to date
0
Altmetric
Original Research

COPD in SARS-CoV-2 pandemic. baseline characteristics related to hospital admissions

, , , , , & show all
Pages 477-484 | Received 15 Oct 2021, Accepted 18 Jan 2022, Published online: 06 Apr 2022

References

  • Lian J, Jin X, Hao S, et al. Analysis of epidemiological and clinical features in older patients with coronavirus disease 2019 (COVID-19) outside wuhan. Clin Infect Dis. 2020;71(15):740–747.
  • Lippi G, Mattiuzzi C, Sanchis-Gomar F, et al. Clinical and demographic characteristics of patients dying from COVID-19 in Italy vs China. J Med Virol. 2020 Oct;92(10):1759–1760.
  • COVID-19@Spain Study Group, Berenguer J, Ryan P, Rodríguez-Baño J, et al. Characteristics and predictors of death among 4035 consecutively hospitalized patients with COVID-19 in Spain. Clin Microbiol Infect. 2020;26(11):1525–1536.
  • Philip KEJ, Lonergan B, Cumella A, et al. COVID-19 related concerns of people with long-term respiratory conditions: a qualitative study. BMC Pulm Med. 2020;20(1):319.
  • Russell R. Covid-19 and COPD: a personal reflection. Int J Chron Obstruct Pulmon Dis. 2020;15:883–884.
  • Graziani D, Soriano JB, Del Rio-Bermudez C, et al. Characteristics and Prognosis of COVID-19 in Patients with COPD. J Clin Med. 2020;9(10):3259.
  • Gómez Antúnez M, Muiño Míguez A, Bendala Estrada AD, et al. SEMI-COVID-19 Network. Clinical characteristics and prognosis of COPD patients hospitalized with SARS-CoV-2. Int J Chron Obstruct Pulmon Dis. 2021;15:3433–3445.
  • Charlson ME, Sax FL, MacKenzie CR, et al. Assessing illness severity: does clinical judgment work? J Chron Dis. 1986;39(6):439–452.
  • World Health O. Collaborating centre for drug statistics M. ATC classification index with DDDs. Oslo: WHO; 2013.
  • McFadyen JD, Schaff M, Peter K. Current and future antiplatelet therapies: emphasis on preserving haemostasis. Nat Rev Cardiol. 2018;15(3):181–191.
  • Chaudhary R, Sharma T, Garg J, et al. Direct oral anticoagulants: a review on the current role and scope of reversal agents. J Thromb Thrombolysis. 2020;49(2):271–286.
  • Quan H, Sundararajan V, Halfon P, et al. Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data. Med Care. 2005;43(11):1130–1139.
  • España PP, Bilbao A, García-Gutiérrez S, et al. COVID-19-Osakidetza Working group. Predictors of mortality of COVID-19 in the general population and nursing homes. Intern Emerg Med. 2021;5:1–10.
  • Hanley JA, McNeil BJ. The meaning and use of the area under a receiver operating characteristic (ROC) curve. Radiology. 1982;143(1):29–36.
  • Hosmer DW, Lemeshow S John Wiley & Sons; Inc., Applied logistic regression. 2nd (New York) ed. 2000.
  • Sullivan LM, Massaro JM, D’Agostino RB. Presentation of multivariate data for clinical use: the Framingham Study risk score functions. Stat Med. 2004;23(10):1631–1660.
  • Steyerberg EW. Clinical prediction models. A practical approach to development, validation, and updating. 2009.
  • Hastie T, Tibshirani R, Friedman J. The elements of statistical learning. data mining, inference, and prediction. 2009.
  • Gebhard C, Regitz-Zagrosek V, Neuhauser HK, et al. Impact of sex and gender on COVID-19 outcomes in Europe. Biol Sex Differ. 2020;11(1):29.
  • *Peckham H, de Gruijter NM, Raine C, et al. Male sex identified by global COVID-19 meta-analysis as a risk factor for death and ITU admission. Nat Commun. 2020;11(1):6317.
  • *Tukiainen T, Villani AC, Yen A, et al. Landscape of X chromosome inactivation across human tissues. Nature. 2017;550(7675):244–248.
  • Scully EP, Haverfield J, Ursin RL, et al. Considering how biological sex impacts immune responses and COVID-19 outcomes. Nat Rev Immunol. 2020;20(7):442–447.
  • *Takahashi T, Ellingson MK, Wong P, et al. Sex differences in immune responses that underlie COVID-19 disease outcomes. Nature. 2020;588(7837):315–320.
  • **Takahashi T, Iwasaki A. Sex differences in immune responses. Science. 2021;371(6527):347–348.
  • Souyris M, Cenac C, Azar P, et al. TLR7 escapes X chromosome inactivation in immune cells. Sci Immunol. 2018;3(19): eaap8855.
  • Al-Lami RA, Urban RJ, Volpi E, et al. Sex hormones and novel corona virus infectious disease (COVID-19). Mayo Clin Proc. 2020;95(8):1710–1714.
  • Hirokawa K, Utsuyama M, Hayashi Y, et al. Slower immune system aging in women versus men in the Japanese population. Immun Ageing. 2013;10(1):19.
  • *Márquez EJ, Chung CH, Marches R, et al. Sexual-dimorphism in human immune system aging. Nat Commun. 2020;11(1):751.
  • Sethi S, Murphy TF. Infection in the pathogenesis and course of chronic obstructive pulmonary disease. N Engl J Med. 2008;359(22):2355–2365.
  • Hewitt R, Farne H, Ritchie A, et al. The role of viral infections in exacerbations of chronic obstructive pulmonary disease and asthma. Ther Adv Respir Dis. 2016;10(2):158–174.
  • *Zheng D, Liwinski T, Elinav E. Inflammasome activation and regulation: toward a better understanding of complex mechanisms. Cell Discov. 2020;6:36.
  • Kroemer A, Khan K, Plassmeyer M, et al. Inflammasome activation and pyroptosis in lymphopenic liver patients with COVID-19. J Hepatol. 2020;73(5):1258–1262.
  • Zou X, Chen K, Zou J, et al. Single-cell RNA-seq data analysis on the receptor ACE2 expression reveals the potential risk of different human organs vulnerable to 2019-nCoV infection. Front Med. 2020;14(2):185–192.
  • Puelles VG, Lütgehetmann M, Lindenmeyer MT, et al. Multiorgan and renal tropism of SARS-CoV-2. N Engl J Med. 2020;383(6):590–592.
  • Liu J, Li Y, Liu Q, et al. SARS-CoV-2 cell tropism and multiorgan infection. Cell Discov. 2021;7(1):17.
  • Marín-Hernández D, Schwartz RE, Nixon DF. Epidemiological evidence for association between higher influenza vaccine uptake in the elderly and lower COVID-19 deaths in Italy. J Med Virol. 2020. DOI:https://doi.org/10.1002/jmv.26120
  • **Fink G, Orlova-Fink N, Schindler T, et al. Inactivated trivalent influenza vaccination is associated with lower mortality among patients with COVID-19 in Brazil. BMJ Evid Based Med. 2020;bmjebm-2020-111549. DOI:https://doi.org/10.1136/bmjebm-2020-111549.
  • Conlon A, Ashur C, Washer L, et al. Impact of the Influenza Vaccine on COVID-19 infection rates and severity. 2021;49:694–700. AJIC Am J Infect Control. DOI:https://doi.org/10.1016/j.ajic.2021.02.012.
  • **Netea MG, Domínguez-Andrés J, Barreiro LB, et al. Defining trained immunity and its role in health and disease. Nat Rev Immunol. 2020;20(6):375–388.
  • Fang L, Karakiulakis G, Roth M. Are patients with hypertension and diabetes mellitus at increased risk for Covid-19 infection? Lancet Respir Med. 2020;8(4):e21.
  • *Mancia G, Rea F, Ludergnani M, et al. Renin-angiotensin-aldosterone system blockers and the risk of Covid-19. N Engl J Med. 2020;382(25):2431–2440.
  • Ren L, Yu S, Xu W, et al. Lack of association of antihypertensive drugs with the risk and severity of COVID-19: a meta-analysis. J Cardiol. 2020;S0914-5087(20): 30353–1.
  • Liao WH, Yang GG, Henneberg M. The renin-angiotensin-aldosterone system inhibitors in COVID-19: from acidosis to ventilation and immunity. Swiss Med Wkly. 2020;150:w20444.
  • Collins GS, Reitsma JB, Altman DG, et al. Transparent reporting of a multivariable prediction model for individual prognosis or diagnosis (TRIPOD): the TRIPOD statement. BMJ. 2015;350(jan07 4):g7594.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.